JAAD Case Reports · 2018 · 28 citations · 6 references
MedicineImmunologyOncologyImmunopathologyImmunotherapyInflammationCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsTumor ImmunopathologyAntigen Presenting CellsCtla-4 InhibitionCytotoxic T Lymphocyte Antigen 4Cytotoxic T-lymphocyte Antigen 4 (Ctla-4) PathwayCytotoxic T-lymphocyte-associated Protein 4 InhibitorsImmune Checkpoint EvasionInhibitory Checkpoint RegulationProgrammed Cell Death Protein 1 (Pd-1) Pathway
Under physiologic conditions, immune checkpoints provide negative signals to control T-cell activation and prevent inflammation-associated tissue destruction. Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), a principal negative regulator of T-cell activation, binds to CD80/CD86 on antigen-presenting cells, dampening the stimulatory signal of CD28 on T cells. Programmed cell death 1 receptor (PD-1) is another inhibitive co-regulator of the CD28/CTLA4 pathway. Excessive activity of either of these checkpoints is one of the underlying mechanisms for cancers, such as melanoma, to evade the immune system.
6
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Tissue Eosinophilia as an Indicator of Drug-Induced Cutaneous Small-Vessel Vasculitis
Soon Bahrami, Janine C. Malone, Kelli G. Webb et al. · Archives of Dermatology · 2006 · 102 citations
Medicine, Dermatology, Pathology +17